Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors.

Human HtrA proteins are serine proteases involved in essential physiological processes. HtrA1 and HtrA3 function as tumor suppressors and inhibitors of the TGF-β signaling pathway. HtrA2 regulates mitochondrial homeostasis and plays a pivotal role in the induction of apoptosis. The aim of the study was to determine whether the HtrA proteins are involved in thyroid carcinogenesis. We used the immunoblotting technique to estimate protein levels of HtrA1, HtrA2, long and short variants of HtrA3 (HtrA3-L and HtrA3-S) and TGF-β1 in tissues of benign and malignant thyroid lesions, and control groups. We found that the levels of HtrA2 and HtrA3-S were higher in thyroid malignant tumors compared to normal tissues and benign tumors. The HtrA3-L level was increased in malignant tumor tissues compared to benign tumor tissues and control tissues from patients with benign lesions, and elevated in normal tissues from patients with thyroid carcinoma compared to normal tissues from patients with benign lesions. We also compared levels of HtrA proteins in follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) and found that these types of carcinoma differed in the expression of HtrA3-S and HtrA1. These results indicate the implication of HtrA proteins in thyroid carcinogenesis suggest that HtrA3 variants may play different roles in cancer development, and that the increased HtrA3-L levels in thyroid tissue could be correlated with the development of malignant lesions. The TGF-β1 levels in tumor tissues were not significantly altered compared to control tissues.

[1]  G. Inman.  Switching TGFβ from a tumor suppressor to a tumor promoter. , 2011, Current opinion in genetics & development.

[2]  M. Urken.  Management of well-differentiated thyroid cancer in 2010: perspectives of a head and neck surgical oncologist. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  B. Jarzab,et al.  Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions , 2010, Molecular and Cellular Endocrinology.

[4]  J. Skorko-Glonek,et al.  HtrA proteins as targets in therapy of cancer and other diseases , 2010, Expert opinion on therapeutic targets.

[5]  J. Cerutti,et al.  Genetic markers differentiating follicular thyroid carcinoma from benign lesions , 2010, Molecular and Cellular Endocrinology.

[6]  J. Chien,et al.  High Temperature Requirement A3 (HtrA3) Promotes Etoposide- and Cisplatin-induced Cytotoxicity in Lung Cancer Cell Lines* , 2010, The Journal of Biological Chemistry.

[7]  A. Baldi,et al.  Methylation Induced Gene Silencing of HtrA3 in Smoking-Related Lung Cancer , 2010, Clinical Cancer Research.

[8]  M. Kreissl,et al.  New targets and therapeutic approaches for endocrine malignancies. , 2009, Pharmacology & therapeutics.

[9]  J. Emerich,et al.  Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. , 2009, Oncology reports.

[10]  J. Chien,et al.  HtrA serine proteases as potential therapeutic targets in cancer. , 2009, Current cancer drug targets.

[11]  J. Chien,et al.  Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration , 2009, Molecular and Cellular Biology.

[12]  A. Schimmer,et al.  Anoikis resistance and tumor metastasis. , 2008, Cancer letters.

[13]  P. Visca,et al.  The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. , 2008, Pharmacogenomics.

[14]  L. Dauphinot,et al.  HtrA1-dependent proteolysis of TGF-β controls both neuronal maturation and developmental survival , 2008, Cell Death and Differentiation.

[15]  J. Emerich,et al.  Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. , 2008, Clinical biochemistry.

[16]  Eva M. Wojcik,et al.  Follicular neoplasm of the thyroid—vanishing cytologic diagnosis? , 2007, Diagnostic cytopathology.

[17]  Fuqing Zeng,et al.  Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  Y. Li,et al.  Distinct expression and localization of serine protease HtrA1 in human endometrium and first‐trimester placenta , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  L. Salamonsen,et al.  Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. , 2006, Gynecologic oncology.

[20]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[21]  B. Vincenzi,et al.  Analysis of HtrA1 serine protease expression in human lung cancer. , 2006, Anticancer research.

[22]  Alfonso Baldi,et al.  Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. , 2006, The Journal of clinical investigation.

[23]  S. Shirasawa,et al.  Oncogenic Ras Inhibits Anoikis of Intestinal Epithelial Cells by Preventing the Release of a Mitochondrial Pro-apoptotic Protein Omi/HtrA2 into the Cytoplasm* , 2006, Journal of Biological Chemistry.

[24]  Y. Li,et al.  Serine Peptidase HTRA3 Is Closely Associated with Human Placental Development and Is Elevated in Pregnancy Serum1 , 2006, Biology of reproduction.

[25]  Raphael A Nemenoff,et al.  Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .

[26]  E. Alnemri,et al.  Regulation of HAX-1 Anti-apoptotic Protein by Omi/HtrA2 Protease during Cell Death* , 2004, Journal of Biological Chemistry.

[27]  F. Oriente,et al.  Omi/HtrA2 Promotes Cell Death by Binding and Degrading the Anti-apoptotic Protein ped/pea-15* , 2004, Journal of Biological Chemistry.

[28]  In-Kyung Kim,et al.  Autocatalytic Processing of HtrA2/Omi Is Essential for Induction of Caspase-dependent Cell Death through Antagonizing XIAP* , 2004, Journal of Biological Chemistry.

[29]  M. Kawaichi,et al.  Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF‐β signaling , 2004, Development, growth & differentiation.

[30]  M. Kawaichi,et al.  HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins , 2004, Development.

[31]  David I. Smith,et al.  A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer , 2004, Oncogene.

[32]  N. Cheong,et al.  Inhibitor of Apoptosis Proteins Are Substrates for the Mitochondrial Serine Protease Omi/HtrA2* , 2003, Journal of Biological Chemistry.

[33]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Jinyu Ren,et al.  Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. , 2003, Genes & development.

[35]  Y. Li,et al.  A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with placentation. , 2003, Molecular human reproduction.

[36]  W. Park,et al.  Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[37]  L. Salamonsen,et al.  Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. , 2003, The Biochemical journal.

[38]  D. Noonan,et al.  The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells , 2002, Oncogene.

[39]  C. Southan,et al.  The HtrA family of proteases: implications for protein composition and cell fate. , 2002, Molecular cell.

[40]  R. Moritz,et al.  HtrA2 Promotes Cell Death through Its Serine Protease Activity and Its Ability to Antagonize Inhibitor of Apoptosis Proteins* , 2002, The Journal of Biological Chemistry.

[41]  J. Downward,et al.  The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* , 2002, The Journal of Biological Chemistry.

[42]  Yuri Lazebnik,et al.  Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction* , 2002, The Journal of Biological Chemistry.

[43]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Zumbrunn,et al.  Primary structure of a putative serine protease specific for IGF‐binding proteins , 1996, FEBS letters.

[46]  C. Georgopoulos,et al.  The HtrA (DegP) protein, essential for Escherichia coli survival at high temperatures, is an endopeptidase , 1990, Journal of bacteriology.

[47]  A. Wozniak,et al.  Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster. , 2008, Acta biochimica Polonica.

[48]  John M. Walker,et al.  Immunochemical Protocols , 2005, Methods In Molecular Biology™.

[49]  U. K. Laemmli,et al.  Cleavage of structural proteins during , 1970 .